m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00441)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
USP7
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | Liver | Mus musculus |
Treatment: Mettl3 knockout liver
Control: Wild type liver cells
|
GSE198513 | |
Regulation |
|
logFC: -7.46E-01 p-value: 2.02E-26 |
More Results | Click to View More RNA-seq Results |
In total 2 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 regulates the expression of Ubiquitin carboxyl-terminal hydrolase 7 (USP7) through m6A methylation and facilitate the invasion, migration and proliferation of HCC cells. Besides, the elevated METTL3 expression was related to worse overall survival. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12.02 | ||
Cell Process | Cell invasion | |||
Cell migration | ||||
Cell proliferation | ||||
In-vitro Model | MHCC97-L | Adult hepatocellular carcinoma | Homo sapiens | CVCL_4973 |
L-02 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6926 | |
Huh-7 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
HCCLM3 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_6832 | |
In-vivo Model | Male nu/nu mice between 4 and 6 weeks of age received subcutaneous injections of equivalent Hep3B cells expressing either LV-shMETTL3 or LV-USP7 within 30 min of harvesting on the right and left flanks. The tumor was weighed after approximately 4 weeks, and the volume was measured every 5 days. | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | Ubiquitin carboxyl-terminal hydrolase 7 (USP7) was upregulated in HCC and associated with METTL3 level positively. USP7 silencing decreased proliferation, migration, and invasion rates of HCC cells. METTL3 promotes HCC to proliferate, migrate, and invade by regulating m6A methylation of USP7. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12.02 | ||
Cell Process | Cell proliferate | |||
Cell migrate | ||||
Cell invade | ||||
In-vitro Model | MHCC97-L | Adult hepatocellular carcinoma | Homo sapiens | CVCL_4973 |
L-02 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6926 | |
Huh-7 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
HCCLM3 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_6832 | |
Fat mass and obesity-associated protein (FTO) [ERASER]
In total 2 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | The m6A demethylase FTO promotes the growth of Non-small cell lung cancer cells by increasing the expression of USP7.Genetic knockdown or pharmacological inhibition (P5091 or P22027) of Ubiquitin carboxyl-terminal hydrolase 7 (USP7) reduced the proliferation rate of lung cancer cells and decreased the capacity of colony formation of lung cancer cells in vitro, whereas lung cancer cells growth inhibition by FTO knockdown is restored by overexertion of USP7. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Responsed Drug | P22077 | Investigative | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
NCI-H522 | Lung adenocarcinoma | Homo sapiens | CVCL_1567 | |
HSAEC (Human small airway epithelial cells) | ||||
RERF-LC-A1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_4402 | |
NCI-H1882 | Lung small cell carcinoma | Homo sapiens | CVCL_1504 | |
NCl-H466 (Human lung cancer cell line) | ||||
In-vivo Model | Equal numbers of A549 cells expressing either control or shFTO were injected subcutaneously, within 30 min of harvesting, over the right and left flanks in male nu/nu mice between 4 and 6 weeks of age. | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | The m6A demethylase FTO promotes the growth of Non-small cell lung cancer cells by increasing the expression of USP7.Genetic knockdown or pharmacological inhibition (P5091 or P22027) of Ubiquitin carboxyl-terminal hydrolase 7 (USP7) reduced the proliferation rate of lung cancer cells and decreased the capacity of colony formation of lung cancer cells in vitro, whereas lung cancer cells growth inhibition by FTO knockdown is restored by overexertion of USP7. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Responsed Drug | P5091 | Investigative | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
NCI-H522 | Lung adenocarcinoma | Homo sapiens | CVCL_1567 | |
HSAEC (Human small airway epithelial cells) | ||||
RERF-LC-A1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_4402 | |
NCI-H1882 | Lung small cell carcinoma | Homo sapiens | CVCL_1504 | |
NCl-H466 (Human lung cancer cell line) | ||||
In-vivo Model | Equal numbers of A549 cells expressing either control or shFTO were injected subcutaneously, within 30 min of harvesting, over the right and left flanks in male nu/nu mice between 4 and 6 weeks of age. | |||
Liver cancer [ICD-11: 2C12]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 regulates the expression of Ubiquitin carboxyl-terminal hydrolase 7 (USP7) through m6A methylation and facilitate the invasion, migration and proliferation of HCC cells. Besides, the elevated METTL3 expression was related to worse overall survival. | |||
Responsed Disease | Hepatocellular carcinoma [ICD-11: 2C12.02] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Cell invasion | |||
Cell migration | ||||
Cell proliferation | ||||
In-vitro Model | MHCC97-L | Adult hepatocellular carcinoma | Homo sapiens | CVCL_4973 |
L-02 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6926 | |
Huh-7 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
HCCLM3 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_6832 | |
In-vivo Model | Male nu/nu mice between 4 and 6 weeks of age received subcutaneous injections of equivalent Hep3B cells expressing either LV-shMETTL3 or LV-USP7 within 30 min of harvesting on the right and left flanks. The tumor was weighed after approximately 4 weeks, and the volume was measured every 5 days. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | Ubiquitin carboxyl-terminal hydrolase 7 (USP7) was upregulated in HCC and associated with METTL3 level positively. USP7 silencing decreased proliferation, migration, and invasion rates of HCC cells. METTL3 promotes HCC to proliferate, migrate, and invade by regulating m6A methylation of USP7. | |||
Responsed Disease | Hepatocellular carcinoma [ICD-11: 2C12.02] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Cell proliferate | |||
Cell migrate | ||||
Cell invade | ||||
In-vitro Model | MHCC97-L | Adult hepatocellular carcinoma | Homo sapiens | CVCL_4973 |
L-02 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6926 | |
Huh-7 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
HCCLM3 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_6832 | |
Lung cancer [ICD-11: 2C25]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | The m6A demethylase FTO promotes the growth of Non-small cell lung cancer cells by increasing the expression of USP7.Genetic knockdown or pharmacological inhibition (P5091 or P22027) of Ubiquitin carboxyl-terminal hydrolase 7 (USP7) reduced the proliferation rate of lung cancer cells and decreased the capacity of colony formation of lung cancer cells in vitro, whereas lung cancer cells growth inhibition by FTO knockdown is restored by overexertion of USP7. | |||
Responsed Disease | Non-small-cell lung carcinoma [ICD-11: 2C25.Y] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Responsed Drug | P22077 | Investigative | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
NCI-H522 | Lung adenocarcinoma | Homo sapiens | CVCL_1567 | |
HSAEC (Human small airway epithelial cells) | ||||
RERF-LC-A1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_4402 | |
NCI-H1882 | Lung small cell carcinoma | Homo sapiens | CVCL_1504 | |
NCl-H466 (Human lung cancer cell line) | ||||
In-vivo Model | Equal numbers of A549 cells expressing either control or shFTO were injected subcutaneously, within 30 min of harvesting, over the right and left flanks in male nu/nu mice between 4 and 6 weeks of age. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | The m6A demethylase FTO promotes the growth of Non-small cell lung cancer cells by increasing the expression of USP7.Genetic knockdown or pharmacological inhibition (P5091 or P22027) of Ubiquitin carboxyl-terminal hydrolase 7 (USP7) reduced the proliferation rate of lung cancer cells and decreased the capacity of colony formation of lung cancer cells in vitro, whereas lung cancer cells growth inhibition by FTO knockdown is restored by overexertion of USP7. | |||
Responsed Disease | Non-small-cell lung carcinoma [ICD-11: 2C25.Y] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Responsed Drug | P5091 | Investigative | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
NCI-H522 | Lung adenocarcinoma | Homo sapiens | CVCL_1567 | |
HSAEC (Human small airway epithelial cells) | ||||
RERF-LC-A1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_4402 | |
NCI-H1882 | Lung small cell carcinoma | Homo sapiens | CVCL_1504 | |
NCl-H466 (Human lung cancer cell line) | ||||
In-vivo Model | Equal numbers of A549 cells expressing either control or shFTO were injected subcutaneously, within 30 min of harvesting, over the right and left flanks in male nu/nu mice between 4 and 6 weeks of age. | |||
P22077
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [3] | |||
Response Summary | The m6A demethylase FTO promotes the growth of Non-small cell lung cancer cells by increasing the expression of USP7.Genetic knockdown or pharmacological inhibition (P5091 or P22027) of Ubiquitin carboxyl-terminal hydrolase 7 (USP7) reduced the proliferation rate of lung cancer cells and decreased the capacity of colony formation of lung cancer cells in vitro, whereas lung cancer cells growth inhibition by FTO knockdown is restored by overexertion of USP7. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
NCI-H522 | Lung adenocarcinoma | Homo sapiens | CVCL_1567 | |
HSAEC (Human small airway epithelial cells) | ||||
RERF-LC-A1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_4402 | |
NCI-H1882 | Lung small cell carcinoma | Homo sapiens | CVCL_1504 | |
NCl-H466 (Human lung cancer cell line) | ||||
In-vivo Model | Equal numbers of A549 cells expressing either control or shFTO were injected subcutaneously, within 30 min of harvesting, over the right and left flanks in male nu/nu mice between 4 and 6 weeks of age. | |||
P5091
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [3] | |||
Response Summary | The m6A demethylase FTO promotes the growth of Non-small cell lung cancer cells by increasing the expression of USP7.Genetic knockdown or pharmacological inhibition (P5091 or P22027) of Ubiquitin carboxyl-terminal hydrolase 7 (USP7) reduced the proliferation rate of lung cancer cells and decreased the capacity of colony formation of lung cancer cells in vitro, whereas lung cancer cells growth inhibition by FTO knockdown is restored by overexertion of USP7. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Cell Process | Ubiquitination degradation | |||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
NCI-H522 | Lung adenocarcinoma | Homo sapiens | CVCL_1567 | |
HSAEC (Human small airway epithelial cells) | ||||
RERF-LC-A1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_4402 | |
NCI-H1882 | Lung small cell carcinoma | Homo sapiens | CVCL_1504 | |
NCl-H466 (Human lung cancer cell line) | ||||
In-vivo Model | Equal numbers of A549 cells expressing either control or shFTO were injected subcutaneously, within 30 min of harvesting, over the right and left flanks in male nu/nu mice between 4 and 6 weeks of age. | |||
References